Comparison of cobas EGFR Mutation Test v2 and PANAMutyper-R- EGFR for Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant

Plasma epidermal growth factor receptor ( ) mutation tests are less invasive than tissue mutation tests. We determined which of two kits is more efficient: cobas Mutation test v2 (cobasv2; Roche Molecular Systems, Pleasanton, CA, USA) or PANAMutyper-R- (Mutyper; Panagene, Daejeon, Korea). We also evaluated whether pleural effusion supernatant (PE-SUP) samples are assayable, similar to plasma samples, using these two kits. We analyzed 156 plasma and PE-SUP samples (31 paired samples) from 116 individuals. We compared the kits in terms of accuracy, assessed genotype concordance (weighted κ with 95% confidence intervals), and calculated Spearman's rho between semi-quantitatively measured -mutant levels (SQIs) measured by each kit. We also compared sensitivity using 47 -mutant harboring samples divided into more-dilute and less-dilute samples (dilution ratio: ≥ or